title: Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
abstract: The efficacy of checkpoint inhibitor therapy illustrates that cancer immunotherapy, which aims to foster the host immune response against cancer to achieve durable anticancer responses, can be successfully implemented in a routine clinical practice. However, a substantial proportion of patients does not benefit from this treatment, underscoring the need to identify alternative strategies to defeat cancer. Despite the demonstration in the 1990's that the detection of danger signals, including the nucleic acids DNA and RNA, by dendritic cells (DCs) in a cancer setting is essential for eliciting host defence, the molecular sensors responsible for recognising these danger signals and eliciting anticancer immune responses remain incompletely characterised, possibly explaining the disappointing results obtained so far upon the clinical implementation of DC-based cancer vaccines. In 2008, STING (stimulator of interferon genes), was identified as a protein that is indispensable for the recognition of cytosolic DNA. The central role of STING in controlling anticancer immune responses was exemplified by observations that spontaneous and radiation-induced adaptive anticancer immunity was reduced in the absence of STING, illustrating the potential of STING-targeting for cancer immunotherapy. Here, we will discuss the relevance of manipulating the STING signalling pathway for cancer treatment and integrating STING-targeting based strategies into combinatorial therapies to obtain long-lasting anticancer immune responses.
authors.affiliation: INSERM U1231, Dijon, France; Université de Bourgogne Franche Comté, Dijon, France.
authors.forename: Thaiz
authors.initials: T
authors.lastname: Rivera Vargas
authors.affiliation: INSERM U1231, Dijon, France; Université de Bourgogne Franche Comté, Dijon, France.
authors.forename: Isis
authors.initials: I
authors.lastname: Benoit-Lizon
authors.affiliation: INSERM U1231, Dijon, France; Université de Bourgogne Franche Comté, Dijon, France; Centre Georges François Leclerc, Dijon, France. Electronic address: lionel.apetoh@inserm.fr.
authors.forename: Lionel
authors.initials: L
authors.lastname: Apetoh
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects; D000818:Animals; D063646:Carcinogenesis / Q000276:immunology; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D004247:DNA / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D007167:Immunotherapy / Q000379:methods*; D007372:Interferons / Q000235:genetics*; D008565:Membrane Proteins / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D015398:Signal Transduction; D000099197:STING Protein
chemical_list: D004247:DNA; D007372:Interferons; D008565:Membrane Proteins; C532857:STING1 protein, human; D000099197:STING Protein
keywords: Adaptive immunity; Anticancer therapies; Cancer immunotherapy; DNA; Danger signal; Innate immunity; STING